Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Amparo Sánchez-Gastaldo"'
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 175-182 (2024)
Abstract Survival beyond 2 years is rare in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with chemotherapy alone. We describe a patient with ES-SCLC who was treated with carboplatin, etoposide and the programmed death-ligand
Externí odkaz:
https://doaj.org/article/7371186711bd4b1a9cf04d73272dbfcf
Autor:
Cristina Candal-Pedreira, Alberto Ruano-Ravina, Virginia Calvo de Juan, Manuel Cobo, José Manuel Trigo, Enric Carcereny, Marc Cucurull, Rafael López Castro, Eduardo Solís García, Amparo Sánchez-Gastaldo, Bartomeu Massutí, Delvys Rodríguez-Abreu, Anna Estival, María Guirado Risueño, María Pamiés Ramón, Rosario García Campelo, Guillermo Alonso-Jáudenes, Carlos Camps, Edel del Barco Morillo, Clara González Ojea, Manuel Dómine, Alfredo Sanchez-Hernandez, Joaquím Bosch-Barrera, María Ángeles Sala González, Mariano Provencio
Publikováno v:
ERJ Open Research, Vol 9, Iss 6 (2023)
Objectives The aim of the study was to ascertain the percentage of Spanish lung cancer cases that would fulfil the lung cancer screening inclusion criteria recommended by the United States Preventive Service Task Force (USPSTF) in 2013 and 2021. Meth
Externí odkaz:
https://doaj.org/article/a612acb88ba047f79e4cc339b0b86a9c
Autor:
Enriqueta Felip, Helena Linardou, Fabrice Barlesi, Michele Maio, Luis Paz-Ares, Jonathan W Goldman, Karim Vermaelen, Osvaldo Arén Frontera, Erika Rijavec, Kevin Jao, Clarisse Audigier-valette, Han Chang, David R Spigel, Neal E Ready, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Stéphanie Bordenave, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Elena Poddubskaya, Samreen Ahmed, Sunney Li, Joseph Fiore, Angelic Acevedo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line treatment in patients with Eastern
Externí odkaz:
https://doaj.org/article/299f8904a44340aa8e9fdf450ecbbc4b
Autor:
Edurne Arriola, MD, PhD, José Manuel Trigo, MD, Amparo Sánchez-Gastaldo, MD, Alejandro Navarro, MD, Coral Perez, MD, Leonardo Crama, MD, Santiago Ponce-Aix, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100266- (2022)
Introduction: SCLC is one of the most lethal malignancies. Classically, staging has been performed using a dual classification distinguishing limited from the extensive stage. This study aimed to evaluate the prognostic value of TNM staging in a real
Externí odkaz:
https://doaj.org/article/ee4d170a7bb04b6b9b63698467121349
Autor:
Miriam Alonso-García, Amparo Sánchez-Gastaldo, Miguel A. Muñoz-Fuentes, Sonia Molina-Pinelo, Laura Boyero, Johana Cristina Benedetti, Reyes Bernabé-Caro
Publikováno v:
Pharmaceuticals, Vol 15, Iss 5, p 533 (2022)
Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy
Externí odkaz:
https://doaj.org/article/6c4ab7e0320e4541932945c15fccdbcf
Autor:
Laura Boyero, José Francisco Noguera-Uclés, Alejandro Castillo-Peña, Ana Salinas, Amparo Sánchez-Gastaldo, Miriam Alonso, Johana Cristina Benedetti, Reyes Bernabé-Caro, Luis Paz-Ares, Sonia Molina-Pinelo
Publikováno v:
Cancers
Volume 15
Issue 5
Pages: 1466
Volume 15
Issue 5
Pages: 1466
Epigenetic mechanisms have emerged as an important contributor to tumor development through the modulation of gene expression. Our objective was to identify the methylation profile of the imprinted C19MC and MIR371-3 clusters in patients with non-sma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d7eef073ac524352a01838c6f9ce83b
Autor:
Javier Salvador Bofill, Clara García Grove, Rocío Morales Herrero, Marta Benavent Viñuales, Begoña Vieites Pérez-Quintela, Ana Gil Torralvo, Reyes Bernabé Caro, Inmaculada Gallego Jiménez, Pilar Sancho Márquez, Amparo Sánchez Gastaldo, Miriam Alonso García, Esaú Monescillo Calzado, Carlos Torrado Martín, Rocío Pérez Velasco, María Ángeles Castilla Moro
Background: The fundamental therapeutic objective in advanced or metastatic cancer is the control of symptoms without detriment to quality of life. Several studies show that cancer patients continue to receive cancer treatment until the last month of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0aac85db626b9295a2b5c826a19b8ca0
https://doi.org/10.21203/rs.3.rs-1463501/v1
https://doi.org/10.21203/rs.3.rs-1463501/v1
Autor:
Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Diz, David Aguiar, Carlos García-Giron, Julia Hidalgo, Carlos Aguado, Jorge Jose García González, Emilio Esteban, Lorenzo Gómez-Aldavarí, Teresa Moran, Oscar Juan, Luís Enrique Chara, Juan Luis Marti, Rafael López Castro, Ana Laura Ortega, Elia Martínez Moreno, Juan Coves, Ana M. Sánchez Peña, Joaquim Bosch-Barrera, Amparo Sánchez Gastaldo, Natalia Fernández Núñez, Edel del Barco, Manuel Cobo, Dolores Isla, Margarita Majem, Fátima Navarro, Virginia Calvo
Background: AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to describe the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::092b61ed5be630f39113b6e100a05c15
https://doi.org/10.21203/rs.3.rs-78194/v1
https://doi.org/10.21203/rs.3.rs-78194/v1
Publikováno v:
Cancer treatment reviews. 60
Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e27684644f479bb62f7e74b3c0524fb
https://pubmed.ncbi.nlm.nih.gov/28898679
https://pubmed.ncbi.nlm.nih.gov/28898679
Autor:
Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Diz, David Aguiar, Carlos García-Giron, Julia Hidalgo, Carlos Aguado, Jorge García González, Emilio Esteban, Lorenzo Gómez-Aldavarí, Teresa Moran, Oscar Juan, Luís Enrique Chara, Juan L. Marti, Rafael López Castro, Ana Laura Ortega, Elia Martínez Moreno, Juan Coves, Ana M. Sánchez Peña, Joaquim Bosch-Barrera, Amparo Sánchez Gastaldo, Natalia Fernández Núñez, Edel del Barco, Manuel Cobo, Dolores Isla, Margarita Majem, Fátima Navarro, Virginia Calvo
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to descri
Externí odkaz:
https://doaj.org/article/8ebc0e8ffdc84091be87e3c5b709643d